Atorolimumab: Difference between revisions
Appearance
Content deleted Content added
Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Citation bot (talk | contribs) Add: s2cid. | Use this bot. Report bugs. | Suggested by BorgQueen | Category:Chemicals that do not have a ChemSpider ID assigned | #UCB_Category 51/851 |
||
(8 intermediate revisions by 7 users not shown) | |||
Line 1: | Line 1: | ||
{{short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| verifiedrevid = |
| verifiedrevid = 458639236 |
||
⚫ | |||
⚫ | |||
| type = mab |
| type = mab |
||
| mab_type = mab |
| mab_type = mab |
||
| source = u |
| source = u |
||
| target = [[Rhesus blood group system|RhD]] |
| target = [[Rhesus blood group system|RhD]] |
||
⚫ | |||
| tradename = |
|||
⚫ | |||
| |
| pregnancy_AU = |
||
| |
| pregnancy_US = |
||
| |
| pregnancy_category = |
||
| |
| legal_AU = |
||
| |
| legal_CA = |
||
| |
| legal_UK = |
||
| |
| legal_US = |
||
| |
| legal_status = |
||
⚫ | |||
| legal_status = |
|||
⚫ | |||
⚫ | |||
| bioavailability = |
|||
⚫ | |||
⚫ | |||
| |
| metabolism = |
||
⚫ | |||
⚫ | |||
| |
| excretion = |
||
⚫ | |||
⚫ | |||
⚫ | |||
| excretion = |
|||
⚫ | |||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
⚫ | |||
| UNII = ZT2TX7WZL7 |
|||
⚫ | |||
⚫ | |||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| PubChem = |
| PubChem = |
||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = |
| DrugBank = |
||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = |
| ChemSpiderID = none |
||
⚫ | |||
| chemical_formula = |
|||
⚫ | |||
| |
| molecular_weight = |
||
| molecular_weight = |
|||
}} |
}} |
||
'''Atorolimumab''' is an [[immunosuppressive drug]] directed against the [[Rhesus factor]].<ref>[http://whqlibdoc.who.int/druginfo/INN_1999_list42.pdf WHO Drug Information]</ref> |
'''Atorolimumab''' is an [[immunosuppressive drug]] directed against the [[Rhesus factor]].<ref>[http://whqlibdoc.who.int/druginfo/INN_1999_list42.pdf WHO Drug Information]</ref><ref>{{cite book | vauthors = Pelletier JP, Mukhtar F | chapter = Chapter 16 - Passive Monoclonal and Polyclonal Antibody Therapies | veditors = Maitta RW |title=Immunologic Concepts in Transfusion Medicine |date=2020 |publisher=Elsevier |location=Philadelphia |isbn=978-0-323-67510-9 | doi = 10.1016/B978-0-323-67509-3.00016-0 |page=267 | s2cid = 213508934 }}</ref> |
||
==References== |
==References== |
||
Line 56: | Line 54: | ||
{{monoclonal-antibody-stub}} |
{{monoclonal-antibody-stub}} |
||
{{antineoplastic-drug-stub}} |
{{antineoplastic-drug-stub}} |
||
[[it:Atorolimumab]] |